Information Provided By:
Fly News Breaks for December 31, 2019
Dec 31, 2019 | 08:24 EDT
Roth Capital analyst Scott Henry assumed coverage of Zynerba with a Buy rating and $12 price target saying the company is an emerging pharmaceutical company focused on cannabinoids. The analyst highlights the company's four key program approaching either clinical readouts or FDA meetings in first half 2020, and believes expectations are low, creating a compelling risk/reward for investors.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE